209 related articles for article (PubMed ID: 15289137)
21. Fibrous membranes in diabetic retinopathy and bevacizumab.
Pattwell DM; Stappler T; Sheridan C; Heimann H; Gibran SK; Wong D; Hiscott P
Retina; 2010; 30(7):1012-6. PubMed ID: 20616680
[TBL] [Abstract][Full Text] [Related]
22. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
[TBL] [Abstract][Full Text] [Related]
23. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease.
Murugeswari P; Shukla D; Rajendran A; Kim R; Namperumalsamy P; Muthukkaruppan V
Retina; 2008 Jun; 28(6):817-24. PubMed ID: 18536597
[TBL] [Abstract][Full Text] [Related]
24. Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31.
Korff T; Dandekar G; Pfaff D; Füller T; Goettsch W; Morawietz H; Schaffner F; Augustin HG
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):468-74. PubMed ID: 16357318
[TBL] [Abstract][Full Text] [Related]
25. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
26. TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy.
Yamaji Y; Yoshida S; Ishikawa K; Sengoku A; Sato K; Yoshida A; Kuwahara R; Ohuchida K; Oki E; Enaida H; Fujisawa K; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3151-7. PubMed ID: 18316703
[TBL] [Abstract][Full Text] [Related]
27. Changes in pericytes and smooth muscle cells in the kitten model of retinopathy of prematurity: implications for plus disease.
Hughes S; Gardiner T; Baxter L; Chan-Ling T
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1368-79. PubMed ID: 17325186
[TBL] [Abstract][Full Text] [Related]
28. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Ozgür E; Heidenreich A; Dagtekin O; Engelmann U; Bloch W
Urol Oncol; 2011; 29(1):78-84. PubMed ID: 19272799
[TBL] [Abstract][Full Text] [Related]
29. Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy.
Gendron RL; Good WV; Adams LC; Paradis H
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):3000-7. PubMed ID: 11687548
[TBL] [Abstract][Full Text] [Related]
30. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
[TBL] [Abstract][Full Text] [Related]
31. Proliferation and activation of vascular endothelial cells in epiretinal membranes from patients with proliferative diabetic retinopathy. An immunohistochemistry and clinical study.
Tang S; Le-Ruppert KC; Gabel VP
Ger J Ophthalmol; 1994 May; 3(3):131-6. PubMed ID: 7518716
[TBL] [Abstract][Full Text] [Related]
32. EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Xue C; Huang Z; Wang J; Dong Y; Zhou X
Can J Ophthalmol; 2009 Apr; 44(2):185-8. PubMed ID: 19491953
[TBL] [Abstract][Full Text] [Related]
33. Comparison of EphA receptor tyrosine kinases and ephrinA ligand expression to EphB-ephrinB in vascularized corneas.
Kojima T; Chung TY; Chang JH; Sayegh R; Casanova FH; Azar DT
Cornea; 2007 Jun; 26(5):569-78. PubMed ID: 17525654
[TBL] [Abstract][Full Text] [Related]
34. Involvement of EphB1 receptor/EphrinB2 ligand in neuropathic pain.
Kobayashi H; Kitamura T; Sekiguchi M; Homma MK; Kabuyama Y; Konno S; Kikuchi S; Homma Y
Spine (Phila Pa 1976); 2007 Jul; 32(15):1592-8. PubMed ID: 17621205
[TBL] [Abstract][Full Text] [Related]
35. Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopathy.
Loukovaara S; Gucciardo E; Repo P; Vihinen H; Lohi J; Jokitalo E; Salven P; Lehti K
Acta Ophthalmol; 2015 Sep; 93(6):512-23. PubMed ID: 25899460
[TBL] [Abstract][Full Text] [Related]
36. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy.
Kobayashi Y; Yoshida S; Zhou Y; Nakama T; Ishikawa K; Arima M; Nakao S; Sassa Y; Takeda A; Hisatomi T; Ikeda Y; Matsuda A; Sonoda KH; Ishibashi T
Mol Vis; 2016; 22():436-45. PubMed ID: 27186070
[TBL] [Abstract][Full Text] [Related]
37. Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Lee TH; Heo JH; Jeong JY; Lee GH; Park DS; Kim TH
Yonsei Med J; 2021 Aug; 62(8):679-690. PubMed ID: 34296545
[TBL] [Abstract][Full Text] [Related]
38. Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
Roldán-Pallarés M; Rollín R; Martínez-Montero JC; Fernández-Cruz A; Bravo-Llata C; Fernández-Durango R
Retina; 2007 Feb; 27(2):222-35. PubMed ID: 17290206
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
40. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Itakura H; Kishi S; Kotajima N; Murakami M
Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
